However, efficacies of these treatments are reduced when a fibroblast TGF-β signaling signature is detected, which is especially common in patients with tumors in which CD8+ T cells are excluded from the tumor parenchyma but are found in fibroblast-rich, collagen-rich peritumoral stroma. This evidence concerns the gene TGFB1 and neoplasm.